McKesson Ventures highlights investment priorities amidst a trail of successful exits
McKesson Ventures is one of the most active investors in the biopharma software sector with Komodo Health, Evidation and M2Gen among its portfolio companies.
McKesson Ventures is one of the most active investors in the biopharma software sector with Komodo Health, Evidation and M2Gen among its portfolio companies.
MedCity spoke with Evidation and BrightInsight, two startups that have recently announced funding rounds, amid a Covid-19 pandemic worsening in the U.S.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Evidation Health, a startup that provides technology for virtual clinical trials, raised $45 million in series D funding. The company plans to use the funds to offer virtual health programs to research participants.
It’s time for entrepreneurs and purchasers to remember that the patient isn’t a component of a healthcare technology plan, they are the point of it.